ClinicalTrials.gg
CompletedNCT01427803Kiefer AUTUpdated Oct 15, 2015Results posted

Actual Use Trial of Naproxen Sodium

A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) in Pain, sponsored by Bayer. Completed at 34 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
778
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
Largest of 25
778 · median 100
Started
2011
with 2 others
Phase 3
5 of 25
none open now
Registered
7th of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one has the largest enrollment, is one of 3 that started in 2011, is one of 5 in phase 3, and was the 7th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

An actual use trial to demonstrate that consumers will not exceed the labeled daily dose of Aleve 24 Hour at an unacceptable rate. Two aspects of consumer use will be evaluated: 1) the frequency at which consumers exceed the label-defined daily dose, thus putting themselves at clinical risk, and 2) the reasons for exceeding the labeled daily dose.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Actual Use Trial
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 12 years of age
  • Report taking OTC analgesics for pain on at least 5 days in the last month
  • Report having had pain at least once in the last 3 months lasting longer than 12 hours or that they believe would have lasted longer than 12 hours if they had not treated it
  • Able to read and understand English
  • Provide written (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent)
  • Provide contact information
  • Purchase the product

Exclusion criteria

Exclusion Criteria:

  • Have participated in a trial involving OTC analgesics in the last 6 months
  • They or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels)
  • Have a history of known allergies to NSAIDs (i.e., naproxen, ibuprofen, aspirin, etc.)
  • Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
  • (Female subjects) are pregnant or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
778 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Naproxen Sodium ER (BAYH6689)

Interventions

06

What researchers measure

Primary outcomes

  1. Estimated Percentage of Misuse for Non-Therapeutic Reasons

    The primary objective of this trial was to determine the percentage of non-therapeutic misuse. Two aspects of consumer use of Aleve 24 Hour were examined: the frequency at which consumers exceeded the label-defined daily dose modified by those who did so for non-therapeutic reasons.

    Time frame: 28 days

Secondary outcomes

  1. Non-therapeutic Reasons for Misuse

    Those subjects in the Reasons for Misuse Cohort who did not state misuse due to need for additional pain relief were categorized to Non-therapeutic misuse.

    Time frame: 28 days

  2. Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course

    This endpoint was an assessment of whether the rate of non-therapeutic misuse exceeded the pre-defined acceptable threshold for non-therapeutic misuse. The difference lay in the estimation of misuse in the Patterns of Use Cohort by using 10-day treatment courses rather than by "use day". A treatment course for each subject began on the first day they recorded taking one or more tablets which was followed by nine consecutive "evaluable days."

    Time frame: 28 days

  3. Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days

    Percentage of participants took \>/= 2 tablets/use day in any 10 use days thus exceeding the label directions during a treatment course.

    Time frame: 28 days

  4. Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day

    Percentage of participants who took product with mean daily use \>/= 2 tablets /use day thus exceeding the label directions on any use day.

    Time frame: 28 days

  5. Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken

    Percentage of participants with at least one dosing occasion where more than one tablet was taken thus exceeding the label directions.

    Time frame: 28 days

  6. Percentage of Dosing Occasions Where More Than One Tablet Was Taken

    Percentage of dosing occasions where more than one tablet was taken thus exceeding the label directions.

    Time frame: 28 days

  7. Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

    Percentage of participants where a dose was taken less than 22 hours after the most recent previous dose thus exceeding the label directions. 22 hrs was chosen to allow for some imprecision in subjects' recollection.

    Time frame: 28 days

  8. Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

    Percentage of dosing occasions where a dose was taken less than 22 hours after the most recent previous dose. 22 hrs was chosen to allow for some imprecision in subjects' recollection

    Time frame: 28 days

07

Results

Posted May 20, 2013

Participant flow

Participant flow — Overall Study
MilestonePatterns of Use CohortReasons for Misuse Cohort
Started526252
Purchased product525252
Baseline assessment516130
Took product508237
Completed463226
Not completed6326
Withdrew: Lost to follow-up3226
Withdrew: Withdrawal by subject200
Withdrew: Unable to complete full treatment period60
Withdrew: Protocol violation10
Withdrew: Physician decision30
Withdrew: Did not take product10

Outcome measures

PrimaryEstimated Percentage of Misuse for Non-Therapeutic Reasons

The primary objective of this trial was to determine the percentage of non-therapeutic misuse. Two aspects of consumer use of Aleve 24 Hour were examined: the frequency at which consumers exceeded the label-defined daily dose modified by those who did so for non-therapeutic reasons.

Time frame:
28 days
Reported as:
Number · Percentage of Participants
Estimated Percentage of Misuse for Non-Therapeutic Reasons
Percentage of ParticipantsNaproxen Sodium ER (BAYH6689)
Estimated Percentage of Misuse for Non-Therapeutic Reasons6.5
SecondaryNon-therapeutic Reasons for Misuse

Those subjects in the Reasons for Misuse Cohort who did not state misuse due to need for additional pain relief were categorized to Non-therapeutic misuse.

Time frame:
28 days
Reported as:
Number · Participants
Non-therapeutic Reasons for Misuse
ParticipantsNaproxen Sodium ER (BAYH6689)
Non-therapeutic Reasons for Misuse52
SecondaryEstimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course

This endpoint was an assessment of whether the rate of non-therapeutic misuse exceeded the pre-defined acceptable threshold for non-therapeutic misuse. The difference lay in the estimation of misuse in the Patterns of Use Cohort by using 10-day treatment courses rather than by "use day". A treatment course for each subject began on the first day they recorded taking one or more tablets which was followed by nine consecutive "evaluable days."

Time frame:
28 days
Reported as:
Number · Percentage of participants
Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course
Percentage of participantsNaproxen Sodium ER (BAYH6689)
Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course5
SecondaryPercentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days

Percentage of participants took \>/= 2 tablets/use day in any 10 use days thus exceeding the label directions during a treatment course.

Time frame:
28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days
Percentage of participantsNaproxen Sodium ER (BAYH6689)
Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days14.9
SecondaryPercentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day

Percentage of participants who took product with mean daily use \>/= 2 tablets /use day thus exceeding the label directions on any use day.

Time frame:
28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day
Percentage of participantsNaproxen Sodium ER (BAYH6689)
Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day4.8
SecondaryPercentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken

Percentage of participants with at least one dosing occasion where more than one tablet was taken thus exceeding the label directions.

Time frame:
28 days
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken
Percentage of participantsNaproxen Sodium ER (BAYH6689)
Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken19.7
SecondaryPercentage of Dosing Occasions Where More Than One Tablet Was Taken

Percentage of dosing occasions where more than one tablet was taken thus exceeding the label directions.

Time frame:
28 days
Reported as:
Number · Percentage of dosing occasions
Percentage of Dosing Occasions Where More Than One Tablet Was Taken
Percentage of dosing occasionsNaproxen Sodium ER (BAYH6689)
Percentage of Dosing Occasions Where More Than One Tablet Was Taken5.4
SecondaryPercentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

Percentage of participants where a dose was taken less than 22 hours after the most recent previous dose thus exceeding the label directions. 22 hrs was chosen to allow for some imprecision in subjects' recollection.

Time frame:
28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Percentage of participantsNaproxen Sodium ER (BAYH6689)
Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose72.5
SecondaryPercentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

Percentage of dosing occasions where a dose was taken less than 22 hours after the most recent previous dose. 22 hrs was chosen to allow for some imprecision in subjects' recollection

Time frame:
28 days
Reported as:
Number · Percentage of dosing occasions
Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Percentage of dosing occasionsNaproxen Sodium ER (BAYH6689)
Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose27.8

Adverse events

Collected over 28 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium ER (BAYH6689)—6/745 (0.8%)89/745 (11.9%)
Most frequent serious events
Most frequent serious events
EventNaproxen Sodium ER (BAYH6689)
overdoseInjury, poisoning and procedural complications1/745
cardiac failure congestiveCardiac disorders1/745
diarrhea haemorrhagicGastrointestinal disorders1/745
viral infectionInfections and infestations1/745
gallbladder disorderHepatobiliary disorders1/745
hypersensitivityImmune system disorders1/745
Most frequent other events
Most frequent other events
EventNaproxen Sodium ER (BAYH6689)
nasopharyngitisInfections and infestations20/745
abdominal pain upperGastrointestinal disorders14/745
headacheNervous system disorders14/745
constipationGastrointestinal disorders12/745
diarrhoeaGastrointestinal disorders11/745
sinusitisInfections and infestations10/745
back painMusculoskeletal and connective tissue disorders8/745

Baseline characteristics

Age, Customized
Age, Customized(Participants)Patterns of Use User PopulationReasons for Misuse Interviewed PopulationTotal
12 to 17 Years303
18 to 24 Years25429
25 to 34 Years631376
35 to 44 Years8128109
45 to 54 Years14230172
55 Years or Older20255257
Sex: Female, Male
Sex: Female, Male(Participants)Patterns of Use User PopulationReasons for Misuse Interviewed PopulationTotal
Female29568363
Male22162283
08

Study locations

34 sites
  • Hoover, Alabama 35226, United States
  • McCalla, Alabama 35111-3406, United States
  • Pinson, Alabama 35126, United States
  • Mesa, Arizona 85202, United States
  • Anaheim, California 92801, United States
  • Oceanside, California 92054, United States
  • Yorba Linda, California 92886, United States
  • Overland Park, Kansas 66209, United States
  • Baltimore, Maryland 21228, United States
  • Andover, Minnesota 55304, United States
  • Elk River, Minnesota 55330, United States
  • Fridley, Minnesota 55432, United States
  • Northfield, Minnesota 55057-2434, United States
  • Rosemount, Minnesota 55068, United States
  • Roseville, Minnesota 55113, United States
  • Kansas City, Missouri 64111, United States
  • Savannah, Missouri 64485, United States
  • St. Joseph, Missouri 64504, United States
  • Albuquerque, New Mexico 87104, United States
  • Albuquerque, New Mexico 87107, United States
  • Taos, New Mexico 87571, United States
  • Bountiful, Utah 84010, United States
  • Hurricane, Utah 84737, United States
  • Layton, Utah 84041, United States
  • Ogden, Utah 84401, United States
  • Salt Lake City, Utah 84102, United States
  • Salt Lake City, Utah 84121, United States
  • Syracuse, Utah 84075, United States
  • West Jordan, Utah 84088, United States
  • Montpelier, Virginia 23192, United States
  • Richmond, Virginia 23221, United States
  • Bellevue, Washington 98007, United States
  • Kenmore, Washington 98028, United States
  • Snohomish, Washington 98290, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Sep 2, 2011
Start
Sep 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
May 20, 2013
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01427803
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 2, 2011
Start date
Sep 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
May 20, 2013
Last update
Oct 15, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion